The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)Markus Borner, A. Roth, Daniel Rauch et al.|Journal of Clinical Oncology|2006Cited by 26
The impact of the irinotecan (IRI) schedule on quality of life in combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer ResearchMarkus Borner, A. Roth, J. Bernhard et al.|Journal of Clinical Oncology|2004Cited by 0